Jennison Associates LLC acquired a brand new stake in shares of Glaukos Co. (NYSE:GKOS – Free Report) through the third quarter, in accordance with its most up-to-date Type 13F submitting with the SEC. The fund acquired 6,080 shares of the medical devices provider’s inventory, valued at roughly $792,000.
A lot of different hedge funds have additionally added to or lowered their stakes within the inventory. EFG Asset Administration North America Corp. elevated its place in shares of Glaukos by 0.5% through the second quarter. EFG Asset Administration North America Corp. now owns 27,205 shares of the medical devices provider’s inventory valued at $3,216,000 after shopping for an extra 128 shares through the interval. Values First Advisors Inc. purchased a brand new stake in Glaukos through the third quarter valued at roughly $25,000. New York State Lecturers Retirement System grew its holdings in shares of Glaukos by 0.4% through the third quarter. New York State Lecturers Retirement System now owns 48,143 shares of the medical devices provider’s inventory value $6,272,000 after buying an extra 200 shares through the interval. KBC Group NV grew its holdings in shares of Glaukos by 16.2% through the third quarter. KBC Group NV now owns 1,445 shares of the medical devices provider’s inventory value $188,000 after buying an extra 201 shares through the interval. Lastly, Encourage Investing LLC raised its place in shares of Glaukos by 6.9% within the third quarter. Encourage Investing LLC now owns 3,193 shares of the medical devices provider’s inventory value $416,000 after buying an extra 206 shares within the final quarter. 99.04% of the inventory is owned by hedge funds and different institutional traders.
Glaukos Value Efficiency
Shares of GKOS opened at $144.00 on Friday. Glaukos Co. has a twelve month low of $59.22 and a twelve month excessive of $146.09. The corporate has a market capitalization of $7.94 billion, a P/E ratio of -47.68 and a beta of 1.02. The agency has a 50 day transferring common of $132.40 and a 200 day transferring common of $123.58. The corporate has a fast ratio of 4.71, a present ratio of 5.54 and a debt-to-equity ratio of 0.19.
Glaukos (NYSE:GKOS – Get Free Report) final posted its earnings outcomes on Monday, November 4th. The medical devices provider reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a detrimental return on fairness of 18.99% and a detrimental web margin of 42.43%. The enterprise had income of $96.70 million through the quarter, in comparison with analyst estimates of $91.50 million. Throughout the identical quarter final yr, the corporate earned ($0.50) EPS. The corporate’s quarterly income was up 23.9% in comparison with the identical quarter final yr. As a bunch, equities analysis analysts anticipate that Glaukos Co. will publish -1.96 earnings per share for the present fiscal yr.
Insiders Place Their Bets
In associated information, COO Joseph E. Gilliam bought 2,275 shares of Glaukos inventory in a transaction on Wednesday, October thirtieth. The inventory was bought at a median value of $138.97, for a complete worth of $316,156.75. Following the completion of the sale, the chief working officer now owns 102,169 shares of the corporate’s inventory, valued at $14,198,425.93. The commerce was a 2.18 % lower of their possession of the inventory. The sale was disclosed in a authorized submitting with the SEC, which is out there at this hyperlink. Additionally, Director Gilbert H. Kliman bought 3,000 shares of the inventory in a transaction dated Monday, September ninth. The shares had been bought at a median value of $130.67, for a complete worth of $392,010.00. Following the completion of the transaction, the director now immediately owns 32,336 shares within the firm, valued at roughly $4,225,345.12. This represents a 8.49 % lower of their place. The disclosure for this sale might be discovered right here. 6.40% of the inventory is owned by insiders.
Analyst Upgrades and Downgrades
A number of brokerages just lately weighed in on GKOS. Truist Monetary upped their value goal on Glaukos from $145.00 to $152.00 and gave the inventory a “purchase” score in a analysis observe on Monday, October 14th. Piper Sandler set a $140.00 goal value on shares of Glaukos in a analysis report on Thursday, October seventeenth. JPMorgan Chase & Co. lifted their value goal on shares of Glaukos from $130.00 to $145.00 and gave the corporate an “obese” score in a analysis report on Tuesday, November fifth. StockNews.com raised shares of Glaukos from a “promote” score to a “maintain” score in a analysis observe on Monday, October twenty first. Lastly, Stifel Nicolaus raised their goal value on shares of Glaukos from $130.00 to $145.00 and gave the corporate a “purchase” score in a analysis observe on Tuesday, September third. 4 analysis analysts have rated the inventory with a maintain score and eight have issued a purchase score to the corporate. In accordance with MarketBeat, Glaukos at present has a consensus score of “Average Purchase” and a median goal value of $134.55.
View Our Newest Report on GKOS
About Glaukos
Glaukos Company, an ophthalmic pharmaceutical and medical expertise firm, focuses on the event of novel therapies for the remedy of glaucoma, corneal issues, and retinal ailments. It affords iStent and iStent inject W micro-bypass stents that improve aqueous humor outflow inserted in cataract surgical procedure to deal with mild-to-moderate open-angle glaucoma.
Learn Extra
Wish to see what different hedge funds are holding GKOS? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Glaukos Co. (NYSE:GKOS – Free Report).
Obtain Information & Scores for Glaukos Day by day – Enter your e mail tackle under to obtain a concise each day abstract of the most recent information and analysts’ rankings for Glaukos and associated corporations with MarketBeat.com’s FREE each day e mail publication.
